|
Daily Medical Update
Heparin-induced thrombocytopenia
Monday, April 20, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The New England journal of medicine (2026) - Randomized Controlled Trial
Key Findings
- Romiplostim prevented CIT-related chemotherapy modification in 84% of patients versus 36% with placebo, with an odds ratio of 10.16 and risk ratio of 2.77.
- Grade 3 or higher adverse events occurred in 37% versus 22%, and thromboembolic events occurred in 2% versus 0%, with no treatment-related serious events leading to discontinuation.
📋 Practice Implication: For persistent chemotherapy-induced thrombocytopenia, romiplostim can be considered when preserving chemotherapy dose intensity outweighs the small observed thromboembolic signal.
|
JAMA (2025) - Randomized Controlled Trial
Key Findings
- Sustained platelet response occurred in 65% of children given eltrombopag versus 35% with standard therapy, a 30% absolute improvement (95% CI, 11%-49%; P = .002).
- There was no between-group increase in the number or type of adverse events despite the higher response rate with eltrombopag.
📋 Practice Implication: In children with newly diagnosed ITP and nonsevere bleeding, eltrombopag has enough efficacy to justify consideration as an earlier steroid-sparing treatment option.
|
The New England journal of medicine (2026) - Randomized Controlled Trial
Key Findings
- Platelet response through week 16 was seen in 91% of participants receiving mezagitamab 600 mg versus 23% of participants receiving placebo.
- Adverse events occurred in 68% versus 69%, while grade 3 or higher events occurred in 18% versus 23%, suggesting similar short-term tolerability to placebo.
📋 Practice Implication: For persistent or chronic ITP after multiple prior therapies, anti-CD38 treatment may become a reasonable escalation pathway if larger trials confirm durability and safety.
|
Pharmacotherapy (2025) - Systematic Review
Key Findings
- Short-term TPO-RA therapy increased thromboembolism versus placebo, 0.72% versus 0.23%, with a Peto odds ratio of 3.25 (95% CI, 1.11-9.51; p = 0.03).
- Arterial thrombosis increased from 0.14% at 6 months or less to 4.2% after 12 months, while venous thrombosis rose from 0.18% to 2.50% by 6 to 12 months and then plateaued near 2.55%.
📋 Practice Implication: When prescribing long-term thrombopoietin-receptor agonists, clinicians should build in arterial and venous thrombosis surveillance rather than focusing only on platelet response.
|
Bone marrow transplantation (2025) - Systematic Review
Key Findings
- The pooled platelet response rate with eltrombopag after allo-HCT was 72% for counts above 30 x 10^9/L and 56% for counts above 50 x 10^9/L.
- Composite response with transfusion independence was 47% for counts above 30 x 10^9/L and 56% for counts above 50 x 10^9/L, while pooled overall survival was 68%.
📋 Practice Implication: After allogeneic transplant, eltrombopag appears most useful as a rescue strategy for persistent thrombocytopenia when the goal is platelet recovery with reduced transfusion dependence.
|
|
💡
Summary
Recent high-significance literature retrieved for this cycle was dominated by broader thrombocytopenia and immune thrombocytopenia studies rather than direct heparin-induced thrombocytopenia investigations, so applicability to HIT is indirect. Across these studies, thrombopoietin-receptor agonists improved platelet recovery or treatment continuity in chemotherapy-induced, pediatric immune, and post-transplant thrombocytopenia, but longer-term exposure carried a measurable thromboembolic penalty. A separate phase 2 trial of anti-CD38 therapy suggests a new option for refractory immune thrombocytopenia, but these findings should not be extrapolated to HIT without disease-specific evidence.
|
|